公司資料
Elicio Therapeutics, Inc. 股價、新聞與催化劑
- 股票代碼:
- ELTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
3.02 USD (-2.27%)
收盤價
最後更新: 2026年8月17日
219M USD
市值
股價為何變動
As of Aug 17, 2026, ELTX closed down 2.27% at $3.02. No new same-company headline was identified in the current news window.
公司概覽
Lymph-Node-Targeted Immunotherapies
Elicio Therapeutics develops immunotherapies designed to traffic directly to lymph nodes, where immune responses are coordinated. Its amphiphile technology links therapeutic payloads to albumin for delivery into lymphatic tissue.
ELI-002 7P
ELI-002 7P is an off-the-shelf therapeutic cancer vaccine targeting seven common KRAS mutations. It is intended to generate mutation-specific T-cell responses in patients with minimal residual disease after surgery.
Pancreatic Cancer Development
The randomized Phase 2 AMPLIFY-7P study is evaluating ELI-002 7P in patients with resected, KRAS-mutated pancreatic ductal adenocarcinoma, using disease-free survival as its primary endpoint.
未來催化劑
- Initiation of a Phase 1 study combining ELI-002 7P with a RAS inhibitor, with or without an anti-PD-1 therapy, in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。